<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Scabies BASHH UK Guideline 2025</h1><h3 class="text-lg font-semibold mt-6 mb-3"><strong>1. New or frequently overlooked points</strong></h3><ul><li><strong>Drug‑supply &amp; cost:</strong> intermittent UK shortages of <em>both</em> permethrin cream and ivermectin tablets since 2023; ivermectin is usually the more expensive option – factor availability &amp; price into regimen choice.</li><li><strong>Application technique is examinable:</strong> head/neck <strong>must</strong> be treated in everyone ≥ 65 y or immunocompromised; clip nails, lift rings, apply to cool dry skin and leave permethrin 12 h (re‑apply to any area washed within that window) – most adults need 30 g but up to 60 g may be required.</li><li><strong>Ivermectin pearls:</strong> give <strong>two 200 µg kg‑1 doses</strong> (Day 1 &amp; 8–15), round <strong>up</strong> to nearest 3 mg tablet, take <strong>with food</strong> to ↑ bioavailability; seek pharmacy advice if weight &gt; 120 kg (doses may exceed SmPC limit). </li><li><strong>Post‑scabetic itch is common</strong> (median 52 d) – counsel patients, treat with emollient ± crotamiton, avoid repeated scabicides.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>2. Biology &amp; epidemiology (high‑yield facts)</strong></h3><ul><li>Sarcoptes scabiei var. hominis: </li><li>fertilised female burrows in stratum corneum, </li><li>lays 1–3 eggs day‑1; </li><li>life‑cycle 10–15 d. </li><li>Mites survive ≤ 36 h off‑host at 21 °C, longer in cool humid environments.</li><li>Transmission is prolonged skin‑to‑skin; fomites matter mainly in crusted scabies.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>3. Clinical spectrum &amp; risk groups</strong></h3><table><tr><td><p><strong>Variant</strong></p></td><td><p><strong>Key features</strong></p></td><td><p><strong>Exam pointers</strong></p></td></tr><tr><td><p><strong>Classical</strong></p></td><td><p>Nocturnal pruritus, excoriated papules &amp; burrows (hands, wrists, genitalia, peri‑umbilical)</p></td><td><p>Back usually spared; head only in infants.</p></td></tr><tr><td><p><strong>Crusted</strong></p></td><td><p>Hyperkeratotic malodorous plaques, minimal itch, huge mite load</p></td><td><p>Risks: immunosuppression, elderly, neuro‑disability, Down syndrome; sepsis risk high. </p></td></tr><tr><td><p><strong>Nail </strong></p></td><td><p>Dystrophic nails </p></td><td><p>Always mention in viva when rash atypical. </p></td></tr><tr><td><p class="mb-3"><strong>Bullous</strong></p></td><td><p class="mb-3">tense bullae in elderly</p></td><td></td></tr><tr><td><p class="mb-3"><strong>Incognito</strong></p></td><td><p class="mb-3">steroid‑modified rash</p></td><td></td></tr></table><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4. Differential diagnosis – memorise common traps</strong></h3><ul><li><strong>Classical:</strong> impetigo, folliculitis, papular urticaria, atopic/contact dermatitis, dermatitis herpetiformis, psoriasis, pityriasis rosea, secondary syphilis, lymphoma/pseudolymphoma (nodular lesions).</li><li><strong>Crusted:</strong> psoriasis, eczema, Darier, pityriasis rubra pilaris, keratoderma, cutaneous T‑cell lymphoma.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>5. Complications to quote</strong></h3><ul><li>Secondary bacterial infection (impetigo → GN, ecthyma, abscess),</li><li> post‑scabetic eczema, </li><li>glomerulonephritis, </li><li>leukocytoclastic vasculitis, sleep‑disturbing pruritus;</li><li> sepsis common in crusted disease.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>6. Diagnosis – three‑tier IACS 2020 (A/B/C) + tests</strong></h3><ul><li>Confirmed = mite/egg/scybala on microscopy, dermoscopy (“delta‑wing” sign) or high‑power imaging.</li><li>Clinical = burrow <strong>OR</strong> typical genital papules <strong>OR</strong> typical rash + ≥ 2 history items (itch/contact).</li><li>Suspected = typical rash + 1 history item <strong>OR</strong> atypical rash + 2 history items.</li><li>Ancillary: adhesive‑tape microscopy, burrow‑ink test, dermoscopy, PCR/ELISA (research). Sensitivity 46–90 %; specificity ~100 %. </li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>7. Management framework</strong></h3><h4 class="text-base font-semibold mt-4 mb-2"><strong>7.1 General / infection‑control advice</strong></h4><ul><li>Treat <strong>all household, sexual &amp; care contacts</strong> within 24 h; use same regimen and second dose 7–14 d later.</li><li>Fomite decontamination:<ul><li> wash ≥ 50 °C × 35 min <strong>OR</strong> </li><li>tumble‑dry high heat 10–35 min OR</li><li> seal non‑washables 4 d at room temp OR</li><li> freeze &lt; ‑10 °C ≥ 5 h. </li></ul></li><li>Avoid sex/close contact until 24 h after first treatment &amp; cleaning done. Provide BAD/PCDS leaflets.</li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>7.2 First‑line regimens (classical scabies)</strong></h4><table><tr><td><p><strong>Drug</strong></p></td><td><p><strong>Dose &amp; schedule</strong></p></td><td><p><strong>Practical pearls</strong></p></td><td><p><strong>GRADE</strong></p></td></tr><tr><td><p><strong>Permethrin 5 % cream</strong></p></td><td><p>Whole‑body incl. neck, face, scalp, nails; 12 h; repeat Day 8–15</p></td><td><p>Apply on cool skin, re‑apply after washing, up to 60 g; assistance for back.</p></td><td><p>1A</p></td></tr><tr><td><p><strong>Ivermectin PO 200 µg kg‑1</strong></p></td><td><p>Day 1 &amp; 8 (≤ 15); round up to 3 mg tabs; take with food</p></td><td><p>Licensed ≥ 15 kg; non‑ovicidal ⇒ second dose vital; safe up to 120 mg in trials. </p></td><td><p>1A</p></td></tr></table><p>Both regimens show similar efficacy in network meta‑analysis. </p><h4 class="text-base font-semibold mt-4 mb-2"><strong>7.3 Alternatives</strong></h4><ul><li><strong>Malathion 0.5 % aqueous</strong> – Day 1 &amp; 8; 24 h contact time (Grade 1D). </li><li><strong>Benzyl‑benzoate 25 %</strong> – two consecutive nightly applications; irritant; unlicensed UK (Grade 2B). </li><li>Topical ivermectin 1 %, sulphur 5 %, spinosad 0.9 % – limited evidence only. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>7.4 Crusted scabies</strong></h4><p>Combine oral ivermectin (3/5/7‑dose schedule) <strong>plus</strong> topical permethrin (daily or alt‑day) <strong>±</strong> keratolytic; decontaminate environment thoroughly; manage secondary sepsis aggressively. </p><h4 class="text-base font-semibold mt-4 mb-2"><strong>7.5 Special situations</strong></h4><ul><li><strong>Pregnancy / breastfeeding:</strong> avoid ivermectin; use permethrin first‑line, malathion second. </li><li><strong>HIV:</strong> treat as immunocompetent unless crusted. </li><li><strong>Heavy weight (&gt;120 kg):</strong> linear PK but consider expert dosing advice. </li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>8. Reactions, follow‑up &amp; treatment failure</strong></h3><ul><li><strong>Adverse events:</strong> permethrin – transient paraesthesia; ivermectin – neuro AE rare (overall AE 5 % vs 4 %).</li><li><strong>Follow‑up:</strong> face‑to‑face review at 4–6 w to check cure &amp; reinforce hygiene. New burrows ≥ 7 d post‑treatment ⇒ retreat. </li><li><strong>Post‑scabetic itch:</strong> persists &gt; 4 w in 1/3; treat with emollient, crotamiton, potent steroid, sedating antihistamine; refer stubborn nodules.</li><li><strong>Treatment failure algorithm:</strong> exclude mis‑diagnosis, poor application, reinfestation, immunosuppression; consider supervised combination therapy (ivermectin + permethrin/malathion/BB) for genuine failure.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>9. Public‑health &amp; audit essentials</strong></h3><ul><li>Notify <strong>UK HSA Health Protection Team</strong> if ≥ 2 linked cases in a closed setting within 8 w; mass, co‑ordinated treatment is key.</li><li><strong>Audit standards (95 %):</strong> (i) correct diagnostic code, (ii) two‑dose first‑line regimen, (iii) written patient info, (iv) STI screen if sexual transmission suspected. </li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>10. Research &amp; exam talking points</strong></h3><ul><li>No standard definition of treatment failure – need better outcome measures &amp; PCR diagnostics. </li><li>Drug‑resistance remains unproven clinically, but lab markers emerging; mention in viva. </li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>11. Exam‑day memory hooks</strong></h3><ul><li><strong>“P‑I‑2‑14”</strong> – Permethrin or Ivermectin; always <strong>2</strong> doses <strong>7–14 d</strong> apart.</li><li><strong>“50 for 50”</strong> – 50 °C for 35 min kills mites/eggs.</li><li><strong>“Head &amp; neck in &gt; 65 y”</strong> – don’t forget scalp coverage.</li><li><strong>Post‑itch lasts “52 d”</strong> – counsel patients.</li><li>Quote IACS criteria &amp; adhesive‑tape microscopy for OSPE.</li></ul><p>Use this streamlined yet comprehensive crib‑sheet for quick recall in FRCPath Part 2 viva/written stations. Good luck!</p>
</div>